BiomX exits phage therapy, pivots to defense/security via DFSL and Zorronet acquisitions

BiomX Inc.

Discontinued all clinical trials; former BiomX Ltd. subsidiary filed for insolvency in Israel in Dec 2025.
Acquired 60% of DFSL (LADAR detection) and 100% of Zorronet (AI security platform) to enter defense markets.
New management: Michael Oster as CEO, David Rokach as CFO appointed in Q1 2026.
Established X Security & Defense subsidiary; committed over $3M for 2026 operations.
Zorronet has projects with Elbit Systems (NIS 500k) and Rafael; DFSL LADAR ~99% detection accuracy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.